EnGeneIC has reported that its second-generation Covid-19 EnGeneIC Dream Vector (EDV) vaccine offers protection against all variants of the SARS-CoV-2 virus in clinical trials.

In the trials, the vaccine showed to act by inducing an immune pathway which is different from other vaccines, to produce ‘high affinity’ antibodies that neutralise all variants.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

At present, the company is carrying out trials of the vaccine in Sydney and Melbourne in Australia.

EnGeneIC dosed 32 healthy subjects with two vaccine doses administered at a gap of three weeks. 

Of those subjects, 27 passed the 28-day safety assessment without any side effects. 

All of them had high-affinity antibodies that could neutralise all Covid-19 variants such as Omicron.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, increased neutralising antibody levels against all variants, including Omicron BA2 and memory response were observed in trial subjects.

EnGeneIC founder and joint CEO Dr Himanshu Brahmbhatt said: “We’re using the power of the immune system to fight infectious diseases like Covid-19 and its mutants by producing high-affinity antibodies. 

“So, even if the spike protein mutates or changes, our antibodies still stick to it tightly and neutralise it.”

As per the trials in subjects with late-stage cancer, the company believes that its Covid-19 vaccine could be effective in immune-compromised people.

Trials in severely immune-compromised people and Australians aged over 75 years with weak immune systems are anticipated to commence in July/August this year in Sydney and Melbourne.

EnGeneIC is also seeking more participants for the trial underway in healthy subjects. 

On receiving Ethics approval next month, enrolment of immune-compromised subjects will begin.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact